GT Biopharma, Inc. (GTBP)
6.27
+0.31
(+5.20%)
USD |
NASDAQ |
Oct 09, 16:00
6.79
+0.52
(+8.29%)
After-Hours: 20:00
GT Biopharma Price to Book Value : 3.140 for Oct. 9, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 2.985 |
| October 07, 2026 | 3.105 |
| October 06, 2026 | 3.19 |
| October 05, 2026 | 3.085 |
| October 02, 2026 | 3.055 |
| October 01, 2026 | 3.105 |
| September 30, 2026 | 3.240 |
| September 29, 2026 | 3.443 |
| September 28, 2026 | 3.405 |
| September 25, 2026 | 3.450 |
| September 24, 2026 | 3.420 |
| September 23, 2026 | 3.556 |
| September 22, 2026 | 3.596 |
| September 21, 2026 | 3.596 |
| September 18, 2026 | 3.586 |
| September 17, 2026 | 3.751 |
| September 16, 2026 | 3.911 |
| September 15, 2026 | 4.507 |
| September 14, 2026 | 5.824 |
| September 11, 2026 | 4.312 |
| September 10, 2026 | 3.095 |
| September 09, 2026 | 2.995 |
| September 08, 2026 | 2.624 |
| September 04, 2026 | 3.017 |
| September 03, 2026 | 3.16 |
| Date | Value |
|---|---|
| September 02, 2026 | 3.543 |
| September 01, 2026 | 3.617 |
| August 31, 2026 | 3.581 |
| August 28, 2026 | 3.756 |
| August 27, 2026 | 3.778 |
| August 26, 2026 | 3.632 |
| August 25, 2026 | 3.752 |
| August 24, 2026 | 3.828 |
| August 21, 2026 | 3.613 |
| August 20, 2026 | 3.530 |
| August 19, 2026 | 3.592 |
| August 18, 2026 | 3.448 |
| August 17, 2026 | 3.568 |
| August 14, 2026 | 3.706 |
| August 13, 2026 | 3.723 |
| August 12, 2026 | 3.782 |
| August 11, 2026 | 3.916 |
| August 10, 2026 | 4.014 |
| August 07, 2026 | 4.008 |
| August 06, 2026 | 3.768 |
| August 05, 2026 | 3.975 |
| August 04, 2026 | 4.083 |
| August 03, 2026 | 3.864 |
| July 31, 2026 | 3.674 |
| July 30, 2026 | 3.854 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.606 |
| Alnylam Pharmaceuticals, Inc. | 22.96 |
| Savara, Inc. | 7.042 |
| Vericel Corp. | 5.544 |
| Biogen, Inc. | 1.770 |
Price to Book Value Related Metrics
| Price | 6.27 |
| Earnings Yield | -1.44K% |
| Market Cap | 11.20M |